[
    [
        {
            "time": "2020-07-10",
            "original_text": "医药生物行业：人血白蛋白与静丙批签发量大幅增长，进口白蛋白占比提升明显，维持“买入”评级",
            "features": {
                "keywords": [
                    "医药生物",
                    "人血白蛋白",
                    "静丙",
                    "批签发量",
                    "进口",
                    "买入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：人血白蛋白与静丙批签发量大幅增长，进口白蛋白占比提升明显，维持“买入”评级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-07-10",
            "original_text": "双林生物重组遭问询：派斯菲科的药品GMP证书曾被收回 问询",
            "features": {
                "keywords": [
                    "双林生物",
                    "重组",
                    "问询",
                    "派斯菲科",
                    "GMP证书"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "双林生物重组遭问询：派斯菲科的药品GMP证书曾被收回 问询",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-07-10",
            "original_text": "A股早报2020年7月10日星期五",
            "features": {
                "keywords": [
                    "A股",
                    "早报"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股早报2020年7月10日星期五",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 4,
                "Source_Recency": 2
            }
        }
    ]
]